DOYLESTOWN, PA. - July 12, 2006 -
The Quigley Corporation (Nasdaq: - QGLY) announced
today that it will launch PainGoes®, a new Over-the-Counter (OTC) pain relieving spray for
temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple
backache, strains, bruises and sprains. The new PainGoes® product is completely independent
of Quigley Pharma's proposed RX formulations currently under development.
The company has contracted the assistance of Rollie Fingers, the baseball Hall of Fame great, for
the introduction and marketing of the product. The initial marketing and product availability will
be exclusively through an Internet Vlog located at www.RolliesFollies.com.
Guy Quigley, President and CEO of Quigley commented, "The era of Vlogs is upon us and this
new media vehicle allows us to test market PainGoes® with minimal expense. Rollie Fingers is
on the air five days a week with fresh new content, and we believe our Vlog will appeal to a
wide variety of sports fans around the world. This is a totally new approach to conventional
advertising and we are hopeful that the retail drug chains, mass merchandisers and many other
diverse sales organizations will join with us in this endeavor to reach people online. We
welcome people to visit www.RolliesFollies.com as often as they like."
PainGoes® is virtually odorless, non-greasy and does not burn when either sprayed on, or gently
rubbed into skin and allowed to dry. It was extremely well received in previous limited test
marketing by people who exercised a great deal, either by working or being involved in sports, as
well as those with various arthritic conditions.
Quigley Corporation's Chief Operations Officer, Charles A. Phillips said, "We believe that the
vast number of high-speed Internet users can best be reached through this new global marketing
approach. Mr. Fingers, through his tales of the Great American Pastime, baseball, as well as
interviews with people of all walks of modern life, will bring an exciting new level of energy to
the Internet."
The Quigley Corporation makes no representation that the US Food and Drug Administration or
any other regulatory agency will grant an Investigational New Drug ("IND") or take any other
action to allow its formulations to be studied or marketed. Furthermore, no claim is made that
potential medicine discussed herein is safe, effective, or approved by the Food and Drug
Administration. Additionally, data that demonstrates activity or effectiveness in animals or in
vitro tests do not necessarily mean the formula test compound, referenced herein will be
effective in humans. Safety and effectiveness in humans will have to be demonstrated by means
of adequate and well controlled clinical studies before the clinical significance of the formula test
compound is known. Readers should carefully review the risk factors described in filings the
Company files from time to time with the Securities and Exchange Commission.
About The Quigley Corporation The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer
and marketer of diversified health products including the COLD-EEZE® family of patented zinc
gluconate glycine (ZIGG(tm)) lozenges, gum and sugar free tablets. In October of 2004, The
Company, through its wholly owned subsidiary, Quigley Manufacturing Inc. acquired two FDA
approved facilities to manufacture its COLD- EEZE® branded lozenges. InnerLight Inc., a
wholly owned subsidiary, was formed in December 2000 for the purpose of introducing new
products to the marketplace through a network of independent distributors. In addition to Over-
The-Counter (OTC) products, the Company has formed Quigley Pharma Inc.
(http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to
introduce a line of naturally derived patented prescription drugs. The Quigley Corporation's
customers include leading national wholesalers and distributors, as well as independent and
chain food, drug and mass merchandise stores and pharmacies.
Forward-Looking Statements
Certain statements in this press release are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk,
uncertainties and other factors that may cause the Company's actual performance or
achievements to be materially different from the results, performance or achievements expressed
or implied by the forward-looking statement. Factors that impact such forward-looking
statements include, among others, changes in worldwide general economic conditions, changes
in interest rates, government regulations, and worldwide competition.
